Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions.

MLA

Harskamp, Ralf E., et al. “Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa Inhibitor Abciximab for Saphenous Vein Graft Interventions.” Cardiovascular Revascularization Medicine, vol. 17, no. 1, Jan. 2016, pp. 19–23. EBSCOhost, https://doi.org/10.1016/j.carrev.2015.09.005.

APA

Harskamp, R. E., Hoedemaker, N., Newby, L. K., Woudstra, P., Grundeken, M. J., Beijk, M. A., Piek, J. J., Tijssen, J. G., Mehta, R. H., & de Winter, R. J. (2016). Procedural and clinical outcomes after use of the glycoprotein IIb/IIIa inhibitor abciximab for saphenous vein graft interventions. Cardiovascular Revascularization Medicine, 17(1), 19–23. https://doi.org/10.1016/j.carrev.2015.09.005

Chicago

Harskamp, Ralf E., Niels Hoedemaker, L. Kristin Newby, Pier Woudstra, Maik J. Grundeken, Marcel A. Beijk, Jan J. Piek, Jan G. Tijssen, Rajendra H. Mehta, and Robbert J. de Winter. 2016. “Procedural and Clinical Outcomes after Use of the Glycoprotein IIb/IIIa Inhibitor Abciximab for Saphenous Vein Graft Interventions.” Cardiovascular Revascularization Medicine 17 (1): 19–23. doi:10.1016/j.carrev.2015.09.005.